AstraZeneca $10 Billion Bet on Rare MC4R Obesity Faces Payer Reality Check

AstraZeneca Bids $10 Billion for Rhythm Pharmaceuticals

AstraZeneca has reportedly made a $10 billion offer to acquire Rhythm Pharmaceuticals, causing Rhythm's shares to jump 24%. The potential transaction, reported by The Wall Street Journal, values Rhythm at $124 per share. Analysts believe Rhythm, a biotech focused on rare neuroendocrine diseases, is a strategic target for large biopharma companies due to its metabolic focus. The key asset is setmelanotide (Imcivree), an injectable weight loss drug recently approved for its third FDA indication, acquired hypothalamic obesity (aHO), with projected sales of $3.6 billion by 2032.

• AstraZeneca's reported $10 billion bid for Rhythm Pharmaceuticals, offering $124 per share, led to a 24% surge in Rhythm's stock. This offer is seen by William Blair as a strategic move, anticipating further bids for the metabolic biotech, which has been identified as a prime acquisition target due to its focus on rare neuroendocrine diseases and its lead asset, setmelanotide.
• The primary driver of Rhythm's valuation is setmelanotide (Imcivree), an injectable weight loss drug. It recently secured its third FDA approval for acquired hypothalamic obesity (aHO), a condition affecting up to 28,000 patients across the U.S., Europe, and Japan. Analysts project Imcivree's sales could reach $3.6 billion by 2032, excluding potential approval for Prader-Willi syndrome.
• Beyond setmelanotide, Rhythm's pipeline includes bivamelagon and RM-718, both targeting aHO and Prader-Willi syndrome, with Phase 3 and Phase 1/2 trials underway or planned. AstraZeneca's CEO, Pascal Soriot, has expressed interest in business development in rare disease, oncology, cardiovascular, immunology, and respiratory, making Rhythm's metabolic and rare disease focus a strong strategic fit for the acquiring company.

The Unmet Need Driving AstraZeneca's Interest in aHO

Acquired hypothalamic obesity (aHO) remains a severe, treatment-refractory disorder with no viable long-term solution. Satisfactory therapy is currently unavailable, and conventional strategies show only modest and variable impact with rapid weight gain and unfavorable long-term outcomes.

• Resistance to lifestyle interventions: Conventional lifestyle modifications remain largely ineffective and patients have unrelenting resistance to basic weight-loss interventions. Combined dietary and lifestyle intervention resulted in decreased BMI, although BMI returned to baseline values on long-term, and traditional obesity treatments, including lifestyle interventions, often fail to achieve sustained weight loss.

• Limited and low-certainty pharmacological evidence: The evidence base was limited by its low quality, small cohorts without control groups, short intervention periods, and inability to perform meta-analysis. According to the GRADE framework, certainty of evidence was low for anthropometric/body composition, metabolic, and behavioral/energy outcomes, with substantial heterogeneity in interventions and outcome measurements and poorly standardized lifestyle interventions.

• Modest efficacy with safety and monitoring burden for GLP-1 receptor agonists: Over a mean follow-up of 44 months, mean weight loss was -4.6% (±12.5), with high interindividual variability; 51% achieved ≥5% weight loss, and 28% ≥10%. Endocrine adverse events occurred in 12% and 10% of patients with adrenal or vasopressin deficiency decompensation, respectively, with 8% requiring hospitalisation. Gastrointestinal intolerance led to treatment discontinuation in 13% of cases, requiring specific endocrine monitoring.

• Attenuated and variable bariatric surgery outcomes with ethical constraints: Bariatric surgery induced a significant weight loss but less than in common obesity, with a 12.5%-point lower weight loss in cases compared with controls and TWL% lower in the craniopharyngioma group than in the control group at 1 and 5 years. Existing literature is largely limited to case reports and series with short term follow-up, and non-reversible procedures are controversial due to ethical and legal considerations in minors.

Imcivree's Clinical Efficacy and Safety in aHO

Recent pharmacologic studies in acquired hypothalamic obesity (aHO) have tested agents targeting distinct energy-homeostasis pathways, including melanocortin-4 receptor agonism, Tesomet, GLP-1 receptor agonists, and intranasal oxytocin. Among these, setmelanotide has shown substantial BMI and hunger reductions in phase 2 and phase 3 trials, while other approaches have shown moderate or nonsignificant weight effects.

Expanding Setmelanotide's Potential Beyond aHO

Setmelanotide is under investigation across several rare genetic obesities driven by impaired melanocortin-4 receptor (MC4R) pathway signaling. These trials span proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) and leptin receptor (LEPR) deficiencies, Bardet-Biedl syndrome (BBS), Alström syndrome, Smith-Magenis syndrome (SMS) and MC4R deficiency.

• POMC/PCSK1 or LEPR deficiency in patients aged 6 years or older (NCT02896192, NCT03287960): single-arm, open-label, multicentre, phase 3 trials in ten hospitals across Canada, the USA, Belgium, France, Germany, the Netherlands, and the UK, with open-label setmelanotide for 12 weeks, followed by an 8-week placebo-controlled withdrawal sequence including 4 weeks each of blinded setmelanotide and placebo treatment, followed by 32 additional weeks of open-label treatment.

• POMC or LEPR deficiency or BBS in patients aged 2-5 years (VENTURE, NCT04966741): 1 year, open-label, multicenter, phase 3 trial across six sites in the USA, the UK, Spain, and Australia, with open-label subcutaneous setmelanotide administered once daily for 52 weeks, starting at 0.5 mg with doses increasing every 2 weeks in 0.5 mg increments until reaching the maximum dose based on weight.

• BBS or Alström syndrome (NCT03746522): multicentre, randomised, 14-week double-blind, placebo-controlled, phase 3 trial followed by a 52-week open-label period at 12 sites in the USA, Canada, the UK, France, and Spain, with participants initially randomized in a 1:1 ratio to receive setmelanotide or placebo for 14 weeks (period 1) and all participants receiving open-label treatment with setmelanotide in period 2 at 3 mg once a day following completion of dose escalation.

• Smith-Magenis syndrome due to RAI1 haploinsufficiency: once-daily setmelanotide injections, with the dose titrated bi-weekly to a maximum of 3 mg over ∼1 month and a full-dose treatment duration of 3mo, assessing percent change in body weight as primary outcome with hunger, waist circumference, body composition, and safety as secondary outcomes.

• MC4R deficiency: 28-day Phase 1b clinical trial evaluating weight loss response to setmelanotide administration in obese MC4R variant carriers, alongside studies of setmelanotide effects on mutant MC4Rs in cells and in rodent studies.